Truvada used as part of a PEP regimen reduces the risk of HIV infection by more than 80%, based on observational research compiled by the National Institutes of Health. That number likely climbs significantly higher when PEP is taken consistently and correctly for the full course. Truvada is not used alone for PEP; it serves as the backbone of a three-drug regimen that also includes a third antiretroviral medication.
What the 80% Figure Actually Means
The earliest formal study of PEP effectiveness, a case-control study of occupational needle-stick injuries, found an 81% reduction in HIV infection among those who received treatment compared to those who received none. That study used only a single drug, not the modern three-drug combination. Today’s regimens, which pair Truvada’s two active ingredients with a third antiretroviral, are expected to perform considerably better.
The challenge is that no randomized controlled trial has ever been conducted to measure PEP’s exact efficacy. Ethically, you can’t give a placebo to someone who may have just been exposed to HIV. So the evidence comes from observational data, animal studies, and extrapolation from related fields like HIV treatment and prevention of mother-to-child transmission. The 80%-plus figure is a floor estimate, not a ceiling.
How Truvada Works in a PEP Regimen
Truvada contains two drugs that both target the same viral enzyme. HIV needs this enzyme, called reverse transcriptase, to copy its genetic material and infect new cells. By blocking that enzyme at two different points, Truvada prevents the virus from replicating inside your body during the narrow window before infection becomes permanent. The third drug in the regimen attacks a different step in the viral life cycle, creating a triple barrier that makes it extremely difficult for HIV to establish itself.
This is why timing matters so much. PEP works by intercepting the virus before it integrates into your immune cells. Once that integration happens, the infection is established and PEP can no longer prevent it.
The 72-Hour Window
PEP must be started within 72 hours of a potential HIV exposure, and sooner is better. The drugs need to reach effective levels in your body while the virus is still vulnerable, before it has replicated enough to gain a permanent foothold. Starting PEP within a few hours of exposure gives you the best chance of success. Every hour of delay reduces effectiveness, and after 72 hours, PEP is not recommended because the window for intervention has likely closed.
Baseline Risk Varies by Exposure Type
PEP’s effectiveness also depends on how likely you were to contract HIV from the specific exposure. Not all exposures carry the same risk. CDC data on per-act transmission probability from an HIV-positive source breaks down as follows:
- Receptive anal intercourse: 138 per 10,000 exposures (about 1.4%)
- Needle stick: 23 per 10,000 exposures (0.23%)
- Insertive anal intercourse: 11 per 10,000 exposures (0.11%)
- Receptive vaginal intercourse: 8 per 10,000 exposures (0.08%)
- Insertive vaginal intercourse: 4 per 10,000 exposures (0.04%)
These numbers represent the risk without any prevention method. PEP reduces whatever your baseline risk is by that 80%-plus margin. So for receptive anal intercourse, the highest-risk sexual exposure, an already small per-act probability drops to a fraction of a percent with proper PEP use.
Completing the Full 28 Days
PEP is a 28-day course. You take the medications once or twice daily (depending on the specific regimen) for four full weeks. Stopping early or skipping doses compromises the drug levels in your body and gives the virus a potential opening to replicate. The effectiveness estimates assume you finish the entire course as prescribed.
Side effects can make adherence difficult. Nausea, fatigue, and headaches are common, particularly in the first week. These effects are temporary, and for most people they become manageable or fade as the body adjusts. If side effects are severe enough that you’re considering stopping, contact your prescriber, as they may be able to adjust the regimen rather than discontinue it.
Testing After PEP
Finishing PEP doesn’t give you an immediate all-clear. HIV tests can take weeks to detect an infection, so follow-up testing is essential. You’ll typically be tested at baseline (when you start PEP) and again after the course is complete, with the final test occurring several weeks to months post-exposure to confirm your status. Until that final test comes back negative, the outcome isn’t certain, though the vast majority of people who complete PEP correctly do not seroconvert.
Why PEP Failures Happen
When PEP does fail, the most common reasons are late initiation (starting too close to the 72-hour mark or beyond), incomplete adherence (missing doses or stopping early), and, in rare cases, exposure to a strain of HIV that is resistant to the drugs in the regimen. Because Truvada-based PEP uses a three-drug combination, resistance to all three simultaneously is uncommon, but it’s one reason clinicians may ask about the source person’s treatment history if it’s known.
The bottom line: Truvada-based PEP is highly effective when started quickly and taken for the full 28 days. The 80% figure from observational data is conservative, and real-world effectiveness with proper adherence is believed to be substantially higher. It is not a guarantee, but it is the best available tool for preventing HIV after a potential exposure has already occurred.